Tumor suppressor p53 is a master regulator of apoptosis and plays key roles in cell cycle checkpoints. p53 responds to metabolic changes and alters metabolism through several mechanisms in cancer. Lactate dehydrogenase A (LDHA), a key enzyme in glycolysis, is highly expressed in a variety of tumors and catalyzes pyruvate to lactate. In the present study, we first analyzed the association and clinical significance of p53 and LDHA in breast cancer expressing wild-type p53 (wt-p53) and found that LDHA mRNA levels are negatively correlated with wt-p53 but not with mutation p53 mRNA levels, and low p53 and high LDHA expression are significantly associated with poor overall survival rates. Furthermore, p53 negatively regulates LDHA expression by directly binding its promoter region. Moreover, a series of LDHA gain-offunction and rescore experiments were carried out in breast cancer MCF7 cells expressing endogenous wt-p53, showing that ectopic expression of p53 decreases aerobic glycolysis, cell proliferation, migration, invasion and tumor formation of breast cancer cells and that restoration of the expression of LDHA in p53-overexpressing cells could abolish the suppressive effect of p53 on aerobic glycolysis and other malignant phenotypes. In conclusion, our findings showed that repression of LDHA induced by wt-p53 blocks tumor growth and invasion through downregulation of aerobic glycolysis in breast cancer, providing new insights into the mechanism by which p53 contributes to the development and progression of breast cancer.
| INTRODUC TI ON
Although normal cells use mitochondrial respiration to provide energy, the majority of tumor cells tend to use aerobic glycolysis, which is also known as the Warburg effect. The Warburg effect is defined as increased dependence on glycolysis for ATP synthesis even in the presence of abundant oxygen rather than the use of the more effective pathway of oxidative phosphorylation.
1,2 Cells absorb metabolites, such as glucose and glutamine, into the metabolic pathway, producing important precursors required for DNA replication, transcription, translation and other growth activities. [3] [4] [5] Therefore, metabolic reprogramming has a strong impact on tumor proliferation, apoptosis, metastasis, and angiogenesis.
Multiple oncogenes and tumor suppressor genes are involved in the regulation of metabolic pathways, affecting the course of malignancy. Recent studies have shown that the regulatory function of wild-type p53 (wt-p53) in energy metabolism represents its key function of tumor suppression. As a tumor suppressor gene, p53 is involved in regulating metabolic pathways through a variety of methods in various types of cancer. 6 As a transcription factor, wt-p53 mainly exerts its function of tumor suppression through transcriptional regulation of its target genes to initiate various cellular responses, including cell cycle arrest, apoptosis, metabolism and ferroptosis. 1, 7, 8 Parkin (PARK2), glutaminase 2 and hexokinase 2 (HK2) are direct targets of p53 and contribute to the functions of p53 in tumor suppression through regulation of energy metabolism. 9, 10 LDHA, a subunit of lactate dehydrogenase (LDH), plays a critical role in regulating glycolysis by catalyzing pyruvate to lactate in the final step of anaerobic glycolysis. 11 This enzyme is receiving a great deal of attention as a potential diagnostic marker or predictive biomarker for many types of cancer and as a therapeutic target for new anticancer treatments. LDHA is highly expressed in various types of cancer and is associated with poor prognosis. 12 Targeting LDHA through RNA interference (RNAi) or using a small-molecule inhibitor may offer novel opportunities for selective therapeutic targeting of cancer cells. 13 The SIRT1-p53-LDHA-Myc pathway plays a vital role in the cell cycle, metabolism, proliferation, differentiation and epigenetics. 14 However, the molecular mechanism of p53 regulation of LDHA expression remains unclear.
In the present study, we analyzed the association and clinical significance of wt-p53 and LDHA expression in breast cancer with wt-p53 expression and explored the mechanism of p53 regulation of LDHA at the transcription level. Furthermore, we carried out rescue experiments to identify the functional role and molecular mechanism of wt-p53 and LDHA in breast cancer in vitro and in vivo. In summary, our findings show that p53 can directly regulate the expression of LDHA at the transcriptional level to control aerobic glycolysis, cell growth and invasion in breast cancer.
| MATERIAL S AND ME THODS

| Cell lines
The human breast cancer cell lines MCF7 (with endogenous wt-p53) and MAD-MB-231 (with endogenous mut-p53) were obtained from 
| Cell transfections
Cells were seeded in a 6-well plate at 2.5 × 10 5 cells per well. When cells achieved 60% to 80% confluency, the cells were transfected with 2.5 μg pcDNA.3/p53 (wt-p53) using Lipofectamine 3000 Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol, and pcDNA3 empty vector was used as a negative control.
| Cell viability and colony-forming assays
Cells were plated in a 96-well plate with five replicates per sample, and cell numbers were counted every day using the CCK-8 assay (Biotool, Houston, TX, USA) for 4 days. For colony-forming assays, cells were plated in 6-well plates at a density of 500 cells per well and cultured for 2 weeks. The medium was replaced with fresh medium every 3 days. After 2 weeks, the medium was removed, and cell colonies were stained with crystal violet (0.1% in 20% methanol) for 10 minutes. Colonies were photographed, and the number of colonies was counted using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
| Cell migration and cell invasion assays
Migration and invasion assays were carried out with 8. 
| Luciferase assay
Cells were cotransfected with LDHA promoter luciferase reporter (pLuc-LDHA) and p53 overexpression vector or control for 48 hours, and pRL-TK was used as an internal control. After transfection, luciferase assays were carried out according to the manufacturer's protocol (Promega, Madison, WI, USA). Data were normalized to the control.
| Chromatin immunoprecipitation assay
Tumor cells (2 × 10
6
) were prepared for ChIP assays using a ChIP Assay (reverse), and Bak1 was used as a positive control, and the PCR primer sequence was as follows: 5′-GGTCAAGGGCAGAGAGAGAA-3′
(forward) and 5′-GGAGCAGGTAGAGCCTCAGA-3′ (reverse). The PCR products were resolved electrophoretically on a 2% agarose gel and visualized using ethidium bromide staining. 
| Immunohistochemistry staining and scores
Paraffin sections were baked for 1 hour at 65°C for deparaffinization and rehydration. After inhibition of endogenous peroxidase activity for protein was done using a method described in our previous studies.
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| Statistical analysis
Data were analyzed using SPSS 16.0 software (Abbott Laboratories, Chicago, IL, USA) and are expressed as mean ± SEM of at least three independent experiments. Student's t test was used to assess the significance of differences between two groups, and ANOVA and Dunnett's multiple comparisons test were used for multiple-group comparisons. Multi-way classification ANOVA was used to evaluate the results of the CCK-8 assay. All statistical tests were two-sided.
P < .05 was considered statistically significant.
| RE SULTS
| Wild-type p53 expression is negatively associated with LDHA expression in human breast cancer tissue
We first monitored wt-p53 and LDHA in a breast cancer expression Consistent with the previous study, p53 expression was reduced in node-positive patients but increased in node-negative patients. In contrast, LDHA expression was increased in node-positive breast cancer patients but reduced in node-negative patients ( Figure 1D ,E).
| Lactate dehydrogenase A is a direct transcriptional target of p53
To investigate whether dynamic expression of p53 could influence LDHA expression, we analyzed mRNA and protein expression of LDHA using qPCR and western blotting analysis, respectively, in 
| Restoring the expression of LDHA can reverse inhibition of the Warburg effect induced by wt-p53 in breast cancer
As a key enzyme, LDHA plays vital roles in aerobic glycolysis in diverse types of cancer, including breast cancer, gastric cancer, renal cell carcinoma, pancreatic cancer, esophageal squamous cell carcinoma and others. 12 Given that p53 decreases LDHA expression levels by directly negatively regulating LDHA, we hypothesized that LDHA mediates the function of p53. To test this hypothesis, we restored the expression of LDHA by overexpressing LDHA in p53-overexpressing cells. As a result, low levels of lactate production and LDH activity and high levels of ATP and glucose concentration and PDH activity were detected in p53-overexpressing MCF7 cells (p53 group),
whereas the values returned to control levels in the P53 plus LDHA group ( Figure 3A-E) . However, no significant change was found in lactate production and LDHA activity when p53 was overexpressed in MDA-MB-231 cells with endogenous mut-p53 ( Figure S1D ,E).
Furthermore, overexpression of p53 enhanced the inhibitory effects 
| Lactate dehydrogenase A reverses p53-mediated tumor growth suppression in vivo
To further corroborate our results in vitro, we established nude 
| D ISCUSS I ON
Lactate is the product of pyruvate catalyzed by LDHA in glycolysis, Taxol-resistant cells show increased LDHA expression and activity, which plays critical roles in Taxol resistance and cancer treatment. 27 Therefore, LDHA might offer a promising therapeutic strategy for breast cancer. Herein, we found that the prognosis of breast cancer patients with high LDHA expression and low p53 expression was poorer than that with low LDHA expression and high p53 expression. In addition, increased LDHA expression was shown in lymph node-positive breast cancer. However, the mechanism underlying LDHA overexpression in breast cancer remains unclear. increased PDH activity by downregulating the expression of mitochondrial PDH kinase 2 (PDK2). 31 In the present study, we show that LDHA expression can be reduced by wt-p53 through inhibiting the activity of the LDHA promoter at the transcriptional level. p53 directly binds to the transcriptional regulation region of LDHA in the BS#1 site. As we know, LDHA catalyzes pyruvate to lactate to promote glycolysis. Thus, reductions in LDHA expression via p53 directly reduce lactate production and thus influence the ability of glycolysis. Therefore, we detected the effect of the p53/LDHA axis on glycolysis. The results showed that low levels of LDH activity and lactate production and high levels of ATP content, PDH In addition, 2-DG, a glucose analogue, significantly inhibits growth, migration, and capillary formation and induces apoptosis. Oxamate, a competitive LDHA inhibitor, inhibits the growth of cervical, breast
and liver cancer cells in vitro. 34 Here, we reported that ectopic expression of p53 could increase 2-DG or oxamate-mediated cell proliferation inhibition, whereas restoring LDHA expression rescues the additive effect of p53. These findings are consistent with the notion that increased glycolysis contributes to the maintenance of cancer cell malignant phenotypes, suggesting that the p53/LDHA axis plays suppressive roles in breast cancer mainly or partially through the inhibition of glycolysis.
Lactate production is related to EMT in cancer cells, and dysregulated lactate metabolism and signaling are key elements in carcinogenesis. [35] [36] [37] ATP levels can inhibit AMPK/p38AMPK signaling and upregulate Glut1 and Glut3 expression, thus regulating glucose uptake and glycolytic enzyme expression. Reactivating p53/ TIGAR and SCO2 pathways can regulate EMT. 21 Our assays showed that overexpressing wt-p53 increases ATP levels and reduces lactate production, whereas restoring LDHA expression rescues the changes in ATP and lactate production that result from p53 overexpression. Therefore, reduced lactate production and increased ATP levels resulting from activation of the p53/LDHA axis inhibit cancer cell migration and invasion. In conclusion, our study showed that wt-p53 inhibits glycolysis and tumor growth and metastasis through direct inhibition of LDHA expression in breast cancer.
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